New therapeutics that modulate chemokine networks

Chemokines are small cytokines that control a wide variety of biological and pathological processes, from immunosurveillance to inflammation, and from viral infection to cancer. The numerous known chemokine receptors have given hope that selective receptor antagonism might be possible, which could allow us to control which cells are recruited and activated at any time and in any place. As chemokine receptors are G-protein-coupled receptors, which are classical targets for the pharmaceutical industry, it is hoped that chemokines could be the first cytokines for which small-molecule receptor antagonists could be developed. Recently, reports of chemokine-receptor antagonists, both in vitro and in animal models of disease, have been published. It is anticipated that this field could produce clinically useful therapies in the next few years.

[1]  R. Fernandez-Botran.  A small-molecule antagonist of human and murine CCR1 receptors , 2001, Expert opinion on investigational drugs.

[2]  H. Sarau,et al.  Discovery of potent and selective phenylalanine derived CCR3 antagonists. Part 1. , 2001, Bioorganic & medicinal chemistry letters.

[3]  H. Sarau,et al.  Discovery of potent and selective phenylalanine derived CCR3 receptor antagonists. Part 2. , 2001, Bioorganic & medicinal chemistry letters.

[4]  R. Hertzberg,et al.  Identification of a Potent, Selective Non-peptide CXCR2 Antagonist That Inhibits Interleukin-8-induced Neutrophil Migration* , 1998, The Journal of Biological Chemistry.

[5]  O. Nishimura,et al.  Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. , 2000, Journal of medicinal chemistry.

[6]  M. Baes,et al.  Lessons from knockout mice. I: Phenotypes of mice with peroxisome biogenesis disorders. , 2003, Advances in experimental medicine and biology.

[7]  D. Hazuda,et al.  1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity. , 2001, Bioorganic & medicinal chemistry letters.

[8]  R. Flinn.  The challenges. , 1979, Delaware medical journal.

[9]  M. Baggiolini,et al.  The Ligands of CXC Chemokine Receptor 3, I-TAC, Mig, and IP10, Are Natural Antagonists for CCR3* , 2001, The Journal of Biological Chemistry.

[10]  Serena Xu,et al.  SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Baggiolini,et al.  Chemokines and their receptors in lymphocyte traffic and HIV infection. , 2000, Advances in immunology.

[12]  A. Trkola,et al.  HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[13]  M. Maccoss,et al.  Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 3: a proposed pharmacophore model for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-[4-(substituted)piperidin-1-yl]butanes. , 2001, Bioorganic & medicinal chemistry letters.

[14]  M. Montjovent,et al.  Extension of Recombinant Human RANTES by the Retention of the Initiating Methionine Produces a Potent Antagonist (*) , 1996, The Journal of Biological Chemistry.

[15]  S. Mccombie,et al.  Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element. , 2001, Bioorganic & medicinal chemistry letters.

[16]  D. Taub,et al.  Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor* , 1998, The Journal of Biological Chemistry.

[17]  B. Rollins,et al.  Chemokines and disease , 2001, Nature Immunology.

[18]  M. Peck,et al.  A Small Molecule Antagonist of Chemokine Receptors CCR1 and CCR3 , 2000, The Journal of Biological Chemistry.

[19]  M. Maccoss,et al.  1,3,4-Trisubstituted Pyrrolidine CCR5 Receptor Antagonists. Part 1. Discovery of the Pyrrolidine Scaffold and Determination of Its Stereochemical Requirements. , 2001 .

[20]  P. Murphy,et al.  Cloning of complementary DNA encoding a functional human interleukin-8 receptor. , 1991, Science.

[21]  J. Fujisawa,et al.  Inhibitory Effects of Small-Molecule CCR5 Antagonists on Human Immunodeficiency Virus Type 1 Envelope-Mediated Membrane Fusion and Viral Replication , 2001, Antimicrobial Agents and Chemotherapy.

[22]  M. Schwarz,et al.  Interfering with chemokine networks--the hope for new therapeutics. , 1999, Current opinion in chemical biology.

[23]  T. Schwartz,et al.  A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. , 1997, Science.

[24]  L. F. Kolakowski,et al.  Functional and biochemical analysis of the cloned Duffy antigen: identity with the red blood cell chemokine receptor. , 1994, Blood.

[25]  R. Horuk,et al.  Species selectivity of a small molecule antagonist for the CCR1 chemokine receptor. , 2000, European journal of pharmacology.

[26]  Antagonists of the Human CCR5 Receptor as Anti‐HIV‐1 Agents. Part 2. Structure—Activity Relationships for Substituted 2‐Aryl‐1‐[N‐(methyl)‐N‐(phenylsulfonyl)amino] ‐4‐(piperidin‐1‐yl)butanes. , 2001 .

[27]  C. Power,et al.  The strategy of blocking the chemokine system to combat disease , 2000, Immunological reviews.

[28]  Pascal Poignard,et al.  Highly Potent RANTES Analogues either Prevent CCR5-Using Human Immunodeficiency Virus Type 1 Infection In Vivo or Rapidly Select for CXCR4-Using Variants , 1999, Journal of Virology.

[29]  W I Wood,et al.  Structure and functional expression of a human interleukin-8 receptor. , 1991, Science.

[30]  D. Hazuda,et al.  Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection. , 2001, Bioorganic & medicinal chemistry letters.

[31]  A. Koch,et al.  Selective lymphocyte chemokine receptor expression in the rheumatoid joint. , 2001, Arthritis and rheumatism.

[32]  Paige Lacy,et al.  A report from the International Eosinophil Society: eosinophils in a tug of war. , 2001, The Journal of allergy and clinical immunology.

[33]  T. Schwartz,et al.  Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. , 1997, Science.

[34]  A. Howell,et al.  A randomized phase-II study of BB-10010 (macrophage inflammatory protein- 1alpha) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy. , 1998, Blood.

[35]  B. Neustadt,et al.  Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist. , 2001, Journal of medicinal chemistry.

[36]  B. Rollins,et al.  Structure/activity analysis of human monocyte chemoattractant protein-1 (MCP-1) by mutagenesis. Identification of a mutated protein that inhibits MCP-1-mediated monocyte chemotaxis. , 1994, The Journal of biological chemistry.

[37]  A. Gronenborn,et al.  Analysis of hydrophobicity in the α and β chemokine families and its relevance to dimerization , 1994 .

[38]  T. Schwartz,et al.  Is there a 'lock' for all agonist 'keys' in 7TM receptors? , 1996, Trends in pharmacological sciences.

[39]  J. White,et al.  Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats. , 2001, The Journal of pharmacology and experimental therapeutics.

[40]  F. Balkwill,et al.  Epithelial cancer cell migration: a role for chemokine receptors? , 2001, Cancer research.

[41]  J. Moore,et al.  AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor , 1998, Nature Medicine.

[42]  J. Moore,et al.  HIV-1 entry inhibitors: Evading the issue , 1999, Nature Medicine.

[43]  M. Maze,et al.  Role of Signal Transduction in Anesthetic Action , 1991 .

[44]  M. Ishikawa,et al.  Discovery of a novel CCR3 selective antagonist. , 2001, Bioorganic & medicinal chemistry letters.

[45]  R. Solari,et al.  An Interleukin 5 Mutant Distinguishes between Two Functional Responses in Human Eosinophils , 1997, The Journal of experimental medicine.

[46]  M. Mack,et al.  Aminooxypentane-RANTES Induces CCR5 Internalization but Inhibits Recycling: A Novel Inhibitory Mechanism of HIV Infectivity , 1998, The Journal of experimental medicine.

[47]  J. Gong,et al.  An Antagonist of Monocyte Chemoattractant Protein 1 (MCP-1) Inhibits Arthritis in the MRL-lpr Mouse Model , 1997, The Journal of experimental medicine.

[48]  C. Cohen,et al.  A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. , 2002, The Journal of clinical investigation.

[49]  Frank Diehl,et al.  Identification of the Binding Site for a Novel Class of CCR2b Chemokine Receptor Antagonists , 2000, The Journal of Biological Chemistry.

[50]  D. Hazuda,et al.  Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection. , 2001, Bioorganic & medicinal chemistry letters.

[51]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[52]  A. Zlotnik,et al.  Chemokines: a new classification system and their role in immunity. , 2000, Immunity.

[53]  H. Sarau,et al.  Identification of Potent, Selective Non-peptide CC Chemokine Receptor-3 Antagonist That Inhibits Eotaxin-, Eotaxin-2-, and Monocyte Chemotactic Protein-4-induced Eosinophil Migration* , 2000, The Journal of Biological Chemistry.

[54]  I. Forbes,et al.  Conformationally restricted indolopiperidine derivatives as potent CCR2B receptor antagonists. , 2001, Bioorganic & medicinal chemistry letters.

[55]  Hiroaki Mitsuya,et al.  Novel Low Molecular Weight Spirodiketopiperazine Derivatives Potently Inhibit R5 HIV-1 Infection through Their Antagonistic Effects on CCR5* , 2001, The Journal of Biological Chemistry.

[56]  A. Naya,et al.  Design, synthesis, and discovery of a novel CCR1 antagonist. , 2001, Journal of medicinal chemistry.

[57]  Dominique Schols,et al.  AMD3100, a Potent and Specific Antagonist of the Stromal Cell-Derived Factor-1 Chemokine Receptor CXCR4, Inhibits Autoimmune Joint Inflammation in IFN-γ Receptor-Deficient Mice1 , 2001, The Journal of Immunology.

[58]  B. Rollins,et al.  MCP-1 in Human Disease , 1999 .

[59]  D. S. Garrett,et al.  High-resolution solution structure of the beta chemokine hMIP-1 beta by multidimensional NMR. , 1994, Science.

[60]  R. Strieter,et al.  Chemokines in Disease , 1996 .

[61]  M. Shiraishi.  Discovery of Novel, Potent, and Selective Small‐Molecule CCR5 Antagonists as Anti‐HIV‐1 Agents: Synthesis and Biological Evaluation of Anilide Derivatives with a Quaternary Ammonium Moiety. , 2000 .

[62]  E. De Clercq,et al.  Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4. , 1999, Journal of medicinal chemistry.

[63]  J. Demartino,et al.  Binding and Functional Properties of Recombinant and Endogenous CXCR3 Chemokine Receptors* , 1998, The Journal of Biological Chemistry.

[64]  E. Clercq,et al.  Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4 , 1997, The Journal of experimental medicine.

[65]  W. Sebald,et al.  Conversion of human interleukin‐4 into a high affinity antagonist by a single amino acid replacement. , 1992, The EMBO journal.

[66]  R. Ransohoff,et al.  CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. , 2001, The American journal of pathology.

[67]  C. Weber,et al.  A Non-peptide Functional Antagonist of the CCR1 Chemokine Receptor Is Effective in Rat Heart Transplant Rejection* , 2001, The Journal of Biological Chemistry.

[68]  I. Charo,et al.  Involvement of chemokine receptor 2 and its ligand, monocyte chemoattractant protein-1, in the development of atherosclerosis: lessons from knockout mice , 2001, Current opinion in lipidology.

[69]  W. Greenlee,et al.  Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection. , 2001, Journal of medicinal chemistry.

[70]  B. Dewald,et al.  RANTES and MCP-3 Antagonists Bind Multiple Chemokine Receptors (*) , 1996, The Journal of Biological Chemistry.

[71]  E A Emini,et al.  Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanes. , 2001, Bioorganic & medicinal chemistry letters.

[72]  A. H. Drummond,et al.  BB-10010: an active variant of human macrophage inflammatory protein-1 alpha with improved pharmaceutical properties. , 1995, Blood.

[73]  R. Horuk,et al.  Discovery of novel non-peptide CCR1 receptor antagonists. , 1999, Journal of medicinal chemistry.

[74]  D. Taub,et al.  Identification and Characterization of a Potent, Selective, and Orally Active Antagonist of the CC Chemokine Receptor-1* , 2000, The Journal of Biological Chemistry.

[75]  O. Nishimura,et al.  A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[76]  Edward J. Fuchs,et al.  Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human Volunteers , 2000, Antimicrobial Agents and Chemotherapy.

[77]  R. Egan,et al.  Effect of Sch 55700, a Humanized Monoclonal Antibody to Human Interleukin-5, on Eosinophilic Responses and Bronchial Hyperreactivity , 1999, Arzneimittelforschung.

[78]  R. Horuk,et al.  CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model. , 2001, Immunology letters.

[79]  M. Schwarz,et al.  Recent developments in modulating chemokine networks , 1999 .

[80]  I. Forbes,et al.  CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound. , 2000, Bioorganic & Medicinal Chemistry Letters.

[81]  M. Ishikawa,et al.  Identification of a potent and nonpeptidyl ccr3 antagonist. , 2001, Biochemical and biophysical research communications.

[82]  Berger Ea.  HIV entry and tropism: the chemokine receptor connection. , 1997 .

[83]  C. Mackay,et al.  Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. , 1998, Immunology today.

[84]  J. Hoxie,et al.  CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4(+) T cells: role of signal transduction. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[85]  ANTAGONISTS OF MONOCYTE CHEMOATTRACTANT PROTEIN 1 IDENTIFIED BY MODIFICATION OF FUNCTIONALLY CRITICAL NH2-TERMINAL RESIDUES , 1995 .

[86]  D. Hazuda,et al.  Combinatorial synthesis of CCR5 antagonists. , 2001, Bioorganic & medicinal chemistry letters.